Despite a prolonged period of policy uncertainty in the U.S.—and the ripple effects across the global life sciences and healthcare industries—executives at health companies are still seeing opportunities amid the tumult. In many cases, they’re finding that the resilient business models they built through disruptions like the pandemic have positioned their companies not just to survive, but to thrive in a new normal for the industry.

In this episode of “The Top Line,” Fierce Pharma’s Fraiser Kansteiner chats with Glenn Hunzinger, PwC’s U.S. health industries leader, about results from the firm’s recent survey on investor sentiment. Focusing on health companies, Hunzinger explains how many innovative drugmakers have managed to capitalize on the shifting environment. Still, he warns that a more uncertain landscape for U.S. innovation and continued tariff pressures on sectors such as medtech could pose challenges down the line.

To learn more about the topics in this episode: 

• AstraZeneca CEO's conservative MFN model excludes reference markets from forecast
• As Johnson & Johnson navigates changing tariff landscape, execs lay out their expectations
• Trump eyes 100% tariff rate for companies that have not struck MFN deals: Bloomberg

See omnystudio.com/listener for privacy information.